Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Trial Profile

A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADU-S100 (Primary) ; Spartalizumab (Primary)
  • Indications Advanced breast cancer; Lymphoma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Nov 2019 Planned primary completion date changed from 30 May 2019 to 31 Mar 2020.
    • 04 Jun 2019 Results (as of 11 Jan 2016; n=66) assessing safety of ADU-S100 and spartalizumab in patients with advanced/metastatic solid tumors or lymphomas, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2019 Results (Data cut-off: April 5, 2019), presented in an Aduro BioTech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top